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830Objective: To evaluate whether myocardial fibrosis influences left ventricular performance in severe aortic
stenosis and to assess its effect on long-term survival after aortic valve replacement.
Methods:Myocardial fibrosis was evaluated in biopsy specimens taken from the interventricular septum in 99
patients undergoing aortic valve replacement because of severe or prevalent aortic stenosis. Clinical and echo-
cardiographic evaluations were performed at a mean follow-up of 6.2  3.0 years. The patients were classified
according to the myocardial fibrosis severity (none or mild in 28, moderate in 52, and severe in 19).
Results: Patients with severe myocardial fibrosis had a dilated left ventricle and positive association between the
left ventricular end-diastolic diameter (R ¼ 0.77, P<.001), left ventricular end-systolic diameter (R ¼ 0.78,
P<.001), left ventricular end-systolic wall stress (R ¼ 0.74, P<.001) and the degree of myocardial fibrosis.
Myocardial fibrosis was inversely related to left ventricular fractional shortening (R¼0.64, P<.001), left ven-
tricular ejection fraction (R¼0.53, P<.001), and left ventricular relative wall thickness (R¼0.70, P<.001).
Patients with a higher grade of myocardial fibrosis had a significantly lower freedom from cardiac death at 10
years (42% 19% vs 89% 6%, P¼ .002), with congestive heart failure the most common cause of death. At
Cox regression analysis, patient age (P ¼ .012), low preoperative transvalvular gradient less than 40 mm Hg
(P ¼ .040), preoperative end-systolic wall stress (P ¼ .046), and preoperative myocardial fibrosis grade
(P ¼ .034) emerged as the strongest independent predictors of mortality.
Conclusions: In patients with severe aortic valve stenosis, the amount of myocardial fibrosis appears to have
significant effect on clinical status and long-term survival after aortic valve replacement. From these results,
we believe that new strategies for the earlier detection of myocardial fibrosis are needed to achieve a better prog-
nostic outcome. (J Thorac Cardiovasc Surg 2012;144:830-7)Left ventricular (LV) hypertrophy produced by pressure
overload in aortic stenosis (AS) is an adaptation that com-
pensates for high intracavitary pressures with the goal of
normalizing wall stress and maintaining adequate cardiac
output.1,2 However, recent studies have questioned the
beneficial role of LV hypertrophy in AS, suggesting that
an increased LV mass might be a predictor of ventricular
dysfunction.3,4 Persistently elevated systolic wall stress
and compromised myocardial perfusion lead to myocyte
degeneration and myocardial fibrosis (MF), with
a significant relationship between the degree of such
morphologic alterations and LV function.5,6 In the
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The Journal of Thoracic and Cardiovascular Surgeffective in normalizing wall stress and maintaining LV
function.7 The decrease in cardiac output might result in
lower than expected transvalvular gradients, with either
a preserved or decreased LV ejection fraction (LVEF).8
This underestimation of AS leads to a late indication for
aortic valve replacement (AVR) with a negative effect on
the prognosis. Recent studies have proved that MF could
be an important morphologic substrate affecting the early
and late results after AVR, especially in patients with severe
AS and a low transvavular gradient.9-11
The aim of the present study was to assess the effect of
MF degree, determined at histologic examination of endo-
cardial biopsy specimens, on LV function and its prognostic
value on mortality in patients requiring AVR for severe AS.
METHODS
All patients gave informed consent to undergo myocardial biopsy per-
formed intraoperatively during AVR and for such specimens to be used
for experimental purposes. Afterward, the local institutional ethics com-
mittee approved the clinical and instrumental evaluation for the present
study.
Patient Population
From January 1999 to December 2006 at Verona University Hospital,
99 patients underwent concomitant isolated AVR and multiple biopsies
of the interventricular septum to study the preoperative morphologicery c October 2012
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
ESWS ¼ end-systolic wall stress
FI ¼ fibrosis index
FTMI ¼ fibrous tissue mass index
HR ¼ hazard ratio
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LVFS ¼ LV fractional shortening
LVPWTd ¼ LV diastolic posterior wall thickness
LVPWTs ¼ LV systolic posterior wall thickness
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MTMI ¼ myocyte tissue mass index
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Dabnormalities of the LV myocardium. During the same period, 1362 pa-
tients underwent ad AVR at our institution. The patients with significant
coronary artery disease, previous cardiac surgery, and a history of myocar-
dial infarction and excessive asymmetric basal septal hypertrophy were ex-
cluded. The limited number of patients included in the present study
represents the experience of a single surgeon (G.F.). The mean patient
age was 71  10 years, with 64 patients (65%) older than 70 years. Of
the 99 patients, 43 (43%) were men and 56 (56%) were women. All pa-
tients had pure or prevalent AS caused by calcified valve degeneration.
The mean New York Heart Association (NYHA) functional class was 2.6
 0.7; 8 patients (8%) were in class I, 33 (33%) in class II, 52 (52%) in
class III, and 6 (6%) in class IV. The preoperative clinical and hemody-
namic data are summarized in Table 1. As a part of the preoperative assess-
ment, all patients underwent selective coronary angiography. A recording
of the intracardiac pressures and transvalvular gradients was possible in
79 patients (80%).
Echocardiographic Evaluation
Standard M-mode and 2-dimensional echocardiographic measurements
were collected according to the American Society of Echocardiography
criteria.12 All Doppler measurements were averaged for 3 cycles in patients
with sinus rhythm or for 5 cycles in those with atrial fibrillation. The sub-
aortic peak and mean velocities, mean pressure gradient, and velocity-time
integral were measured from the pulsed-wave Doppler recordings in the
5-chamber apical view, with the sample volume placed just below the point
of fast flow acceleration. The severity of AS was assessed by measuring the
aortic valve area and peak and mean transvalvular gradients calculated us-
ing a standard formula based on the principle of continuity of flow. The LV
end-diastolic diameter (LVEDD), LVend-systolic diameter (LVESD), dia-
stolic and systolic septal wall thickness, and diastolic and systolic inferior
wall thickness (LVPWTd and LVPWTs) were measured using M-mode
echocardiography. LV fractional shortening (LVFS) was calculated as fol-
lows: 1003 (LVEDDLVESD)/LVEDD. The ejection fraction was calcu-
lated according to Simpson’s rule: ejection fraction ¼ (end-diastolic
volume end-systolic volume)/end-diastolic volume. The LV mass was
calculated according to the Devereux formula13 and indexed for body sur-
face area (LV mass index). The relative wall thickness (RWT) was calcu-
lated according to the formula: RWT ¼ (2 3 LVPWTd)/LV end-diastolic
internal dimension. The LVend-systolic wall stress (ESWS) was calculatedThe Journal of Thoracic and Caas follows: ESWS ¼ 0.334 3 P 3 LVESD/[LVPWTs 3 (1þLVPWTs/
LVESD)], where P is the left ventricular peak systolic pressure calculated
as the sum of systolic blood pressure taken by sphygmomanometry plus the
peak aortic gradient evaluated by Doppler.14 Patients with ESWS greater
than 120 kdyne/cm2 were considered to have inadequate cardiac hypertro-
phy, calculated as the mean standard deviation of ESWS values obtained
by Serneri and colleagues7 for the same pathologic finding.
Surgical Data
All patients underwent surgery under moderate hypothermic cardiopul-
monary bypass with topical cooling and infusion of anterograde and/or ret-
rograde cold blood cardioplegia. After aortic crossclamping through
a transverse aortotomy, the aortic valve leaflets were excised, and careful
decalcification of the aortic annulus was performed, if necessary. Prosthe-
ses were implanted using multiple interrupted stitches buttressed by suban-
nular Teflon felts. The following prostheses were implanted: Hancock
porcine (Medtronic, Minneapolis, MN) in 44 patients (45%); Edwards
Perimount pericardial (either standard or Magna models; Edwards Life-
sciences, Irvine, CA) in 26 (26%); Sorin Bicarbon bileaflet (Sorin Biomed-
ica, Saluggia, Italy) in 15 (15%); Carbomedics bileaflet (Sorin Biomedica)
in 10 (10%); and Sorin Freedom pericardial stentless (Sorin Biomedica) in
4 (4%). The prosthetic size was 21 mm in 25 patients (25%), 23 mm in 55
(56%), 25 mm in 17 (17%), and 27 mm in 2 (2%). A total of 16 patients
underwent concomitant procedures, including mitral valve surgery in 12
(12%) and ascending aorta replacement in 4 (4%). A total of 10 patients
underwent concomitant limited myectomy.
Endomyocardial Biopsy and Patient Groups
After removal of the aortic valve, 3 samples of myocardial tissue were
taken using a standard bioptome from the basal LV septum. All samples
were stored overnight in 10% formaldehyde solution, embedded in paraf-
fin, cut in 2-mm-thick sections, and stained with hematoxylin-eosin and
Masson’s trichrome stain. The relative volume of myocardial muscle and
fibrous tissuewas determined by point counting using a 103 10 grid at a to-
tal magnification of 1003.15,16 A hypertrophied myocyte (defined as a cell
diameter>15 mm) tissue index (myocyte tissue mass index [MTMI]) was
calculated as a percentage by dividing the sum of the hypertrophic areas of
the section by the sume of the total tissue area. It was graded as mild
(<20%), moderate (20–50%), and severe (>50%). The MTMI was
expressed as the percentage of hypertrophied myocytes 3 LV mass
index/100 (g/m2).15 The fibrosis index (FI) was calculated by dividing
the sum of the fibrotic areas of the section by that of the total tissue area
and expressed as a percentage, as described by Tanaka and collegues.17 Ac-
cording to the FI, the patients were classified as having no or mild fibrosis
(FI<20%; group 1), moderate fibrosis (FI, 20–50%; group 2), or severe
fibrosis (FI>50%; group 3; Figure 1). The fibrous tissue mass index
(FTMI) was estimated as FI 3 LV mass index/100 (g/m2).18
Although FI is a valuable parameter to assess the extent of pathologic
changes in the myocardium, we also used the FTMI for better correlation
with the LV mass value, as suggested by Lund and associates.19
Data Collection and Follow-up
All clinical and pathologic data obtained from the database of our insti-
tution were entered into designed study forms. Next, the clinical and echo-
cardiographic data were prospectively collected at 6 and 12 months and
yearly thereafter. The last follow-up information for hospital survivors
was obtained during a 6-month interval ending in June 2010. Unsuccessful
attempts to trace patients were followed by contact with the family mem-
bers or the referring physicians. Considered as an end point, the last follow-
up information, efforts were made to assess the cause of late deaths. The
cause of late mortality was defined complying with recently revised guide-
lines.20 In particular, cardiac death was defined as any documented death
related to a cardiac event, such as myocardial infarction or progressive car-
diac failure or any sudden, unexplained death.rdiovascular Surgery c Volume 144, Number 4 831
TABLE 1. Baseline characteristics
Characteristic All (n ¼ 99)
MF grade
P value1 (n ¼ 28) 2 (n ¼ 52) 3 (n ¼ 19)
Mean age (y) 71  10 70  9 72  9 72  13 .757
Gender .833
Male 43 11 24 8
Female 56 17 28 11
AF 13 (13) 4 (14) 6 (12) 3 (16) .875
Diabetes 20 (20) 8 (29) 8 (15) 4 (21) .373
Arterial hypertension 37 (37) 9 (32) 17 (33) 11 (58) .121
PVD 16 (16) 9 (32) 4 (8) 3 (16) .018
Angina 36 (36) 10 (36) 19 (37) 7 (37) .923
Syncope 15 (15) 5 (18) 7 (15) 3 (16) .844
Mean NYHA 2.6  0.7 2.4  0.7 2.5  0.7 3.1  0.6 .001
LVEDD (mm) 54  7 47  6 54  5 64  5 <.001
LVESD (mm) 37  8 29  6 37  5 47  5 <.001
LVPWTd (mm) 12  2 14  1 12  2 10  2 <.001
LVPWTs (mm) 16  3 17  2 16  2 13  2 <.001
LVSWTd (mm) 14  2 16  1 14  2 11  1 <.001
LVSWTs (mm) 18  3 20  2 18  2 14  2 <.001
LVFS (%) 33  8 39  6 33  6 24  5 <.001
RWT 0.47  0.13 0.61  0.10 0.44  0.07 0.31  0.04 <.001
LVEF (%) 53  9 57  7 55  8 42  7 <.001
LVEF<50% 29 (29) 3 (11) 12 (23) 14 (74) <.001
LVMI (g/m2) 194  32 196  33 194  30 190  38 .837
ESWS (kdyne/cm2) 115  56 65  20 109  29 206  41 <.001
RVSP (mm Hg) 38  11 37  7 37  11 44  17 .232
RVDP (mm Hg) 3.6  2.2 3.6  1.9 3.5  2.4 3.8  2.4 .966
PASP (mm Hg) 36  12 35  9 35  11 43  19 .207
PADP (mm Hg) 14  7 14  6 14  6 18  10 .229
MWP (mm Hg) 15  8 14  7 14  7 19  12 .192
Aortic PG (mm Hg) 78  18 78  18 79  18 74  19 .599
Aortic MG (mm Hg) 49  13 50  11 51  14 44  12 .175
Aortic MG<40 mm Hg 23 (23) 4 (14) 10 (19) 9 (47) .018
Aortic VAi (cm2/m2) 0.39  0.10 0.39  0.08 0.39  0.09 0.40  0.10 .789
FTMI (g/m2) 61  32 24  9 65  17 104  20 <.001
MTMI (g/m2) 79  34 75  45 82  30 77  21 .002
Data presented as mean  standard deviation or numbers, with percentages in parentheses. MF, Myocardial fibrosis; AF, atrial fibrillation; PVD, peripheral vascular disease;
NYHA, New York Heart Association functional class; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end-systolic diameter; LVPWTd, left ventricular
diastolic posterior wall thickness; LVPWTs, left ventricular systolic posterior wall thickness; LVSWTd, left ventricular diastolic septal thickness; LVSWTs, left ventricular systolic
septal thickness; LVFS, left ventricular fractional shortening; RWT, relative wall thickness; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; ESWS, end
systolic wall stress; RVSP, right ventricular systolic pressure; RVDP, right ventricular diastolic pressure; PASP, pulmonary artery systolic pressure; PADP, pulmonary artery di-
astolic pressure; MWP, mean wedge pressure; PG, peak gradient; MG, mean gradient; VAi, indexed valve area; FTMI, fibrosis tissue mass index; MTMI, myocyte tissue mass
index.
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The data are presented as the mean  standard deviation for contin-
uous variables and as simple percentage for categorical variables. A
comparison of the mean values was performed with the paired and un-
paired t test or analysis of variance method in the case of more than 2
groups in the analysis. The percentages were compared using the chi-
square or Wilcoxon tests, as appropriate. Linear regression analyses
were used to assess the correlation between MF and LV function. Over-
all survival and freedom from cardiac death were determined using
Kaplan-Meier actuarial analysis and are expressed as the percentage
of patients who were event free  standard error. Cox regression anal-
ysis was used to examine the effects of the predictors of cardiac death.
Statistical analyses were performed using SPSS, version 16.0.1 (SPSS,
Chicago, Ill).832 The Journal of Thoracic and Cardiovascular SurgRESULTS
Endomyocardial Biopsies
According to the myocardial morphology of the septal
biopsy specimens, the patients were divided into 3
groups (Table 1). Group 1 (no or mild MF) included 28
patients (28%) with a mean FTMI of 21  8 g/m2 and
a mean MTMI of 65  39 g/m2. Group 2 (moderate
MF) included 52 patients (53%) with mean FTMI of
66  20 g/m2 and a mean MTMI of 83  33 g/m2. Group
3 (severe MF) included 19 patients (19%) with a mean
FTMI of 130  29 g/m2 and a mean MTMI of 96 
28 g/m2.ery c October 2012
FIGURE 1. Sample of myocardium stained with Masson’s tricrome
(253) showing severe fibrous tissue between myocardial cells.
FIGURE 2. Correlation between myocardial fibrosis tissue mass index
(FTMI) and baseline echocardiographic characteristics: left ventricular
end diastolic diameter (LVEDD), left ventricular end-systolic diameter
(LVESD), and end-systolic wall stress (ESWS).
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Morphology
The baseline patient characteristics are listed in Table 1.
The NYHA functional class was significantly better
in groups 1 and 2 than in group 3. In the entire popula-
tion, the patients with impaired LV function had a greater
mean wedge pulmonary pressure and right ventricular
systolic pressure. Patients with severe fibrosis showed
signs of cardiomiopathy with myocardial dysfunction
(LVEF, 42%  7%), dilated LV (LVEDD, 64  5 mm;
LVESD, 47  5 mm) and reduced LV wall thickness
(RWT, 0.31  0.06). Thus, a positive association was
found between the LVEDD (R ¼ 0.77, P<.001), LVESD
(R ¼ 0.78, P<.001), and ESWS (R ¼ 0.74, P<.001) and
the degree of FTMI (Figure 2). In contrast, MF was in-
versely related to LVFS (R ¼ 0.64, P< .001), LVEF
(R ¼0.53, P< .001) and RWT (R ¼0.70, P< .001;
Figure 3). Severe AS with a low transvalvular gradient
was found in 23 patients (23%), regardless of the
LVEF, but most of the patients with a low transvalvular
gradient and low LVEF were found in the group with
the greatest degree of MF (47% and 74% of the group,
respectively).
Adequate LV hypertrophy was found in 63 patients
(mean ESWS, 81  22 kdyne/cm2), and 36 had an inade-
quate cardiac hypertrophy (mean ESWS, 176  47 kdyne/
cm2). In patients with adequate hypertrophy, the increase
in LV mass was mainly related to the increase in the LV
wall thickness (LVPWTs, 18  2 mm vs 14  2 mm,
P< .001). However, in patients with an elevated ESWS,
the increase in LV mass was due to a larger increase in
the LV diameters (LVESD, 32  6 mm vs 44  5 mm,
P< .001) and lower RWT (0.54  0.10 vs 0.34  0.06,
P< .001). Finally, the FTMI was significantly greater inThe Journal of Thoracic and Capatients with inadequate hypertrophy (88  27 g/m2 vs 46
 23 g/m2, P<.001).Clinical Data and Follow-up
The extent of histologically determined MF correlated
closely with the preoperative functional class (P< .001).
Hospital mortality was 3%, with 2 deaths from cardiac fail-
ure and 1 from acute renal failure; 7 patients experienced
cerebrovascular events (7.%), 14 had low output syndrome
(14%), and 2 had acute renal failure requiring hemodialysis
(2%). A total of 96 hospital survivors were followed up for
1 to 12 years, with a mean follow-up of 6.2  2.9 years. A
total of 32 late deaths occurred due to progressive heartrdiovascular Surgery c Volume 144, Number 4 833
FIGURE 3. Correlation between myocardial fibrosis tissue mass index
(FTMI) and baseline left ventricular fractional shortening (LVFS), left ven-
tricular ejection fraction (LVEF), and relative wall thickness (RWT).
FIGURE 4. Actuarial freedom from cardiac death at 10 years according to
myocardial fibrosis grade.
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Dfailure in 14 patients, stroke in 7, neoplasia in 6, myocardial
infarction in 3, senectus in 1, and sudden cardiac death in 1.
The overall actuarial survival at 10 years was 53%  6%.
Patients with a higher grade of MF demonstrated signifi-
cantly lower freedom from cardiac death at 10 years
(42%  19% vs 89%  6%, P ¼ .002; Figure 4). In the
subgroup of 20 patients who died of a cardiac cause, the pre-
operative NYHA class, LV dysfunction, and the amount of
MF were significantly greater than in those who survived
(Table 2). Patient age (hazard ratio [HR], 1.09; P ¼ .012),
preoperative transvalvular gradient less than 40 mm Hg
(HR, 2.82; P ¼ .040), preoperative ESWS (HR, 1.01;
P ¼ .046), and preoperative FTMI (HR, 1.02; P ¼ .034)
emerged as the strongest independent predictors of cardiac834 The Journal of Thoracic and Cardiovascular Surgmortality. At the last follow-up visit, the mean NYHA class
was 2.3  0.9, with 17 patients (17%) in functional class I,
46 (48%) in class II, 23 (24%) in class III, and 10 (10%) in
class IV. Patients with a mild to moderate grade of fibrosis at
baseline showed improvement in the NYHA functional
class and LVEF, with a marked reduction of the LVmass in-
dex. However, patients with severe fibrosis showed only
a slight clinical improvement without any significant
changes in LV size, LVFS, and LVEF (Table 3).DISCUSSION
Patients with AS have advanced structural alterations of
the left ventricle characterized by MF and varying degrees
of myocyte degeneration.5,21,22 Such changes occur
predominantly in the subendocardial layers, leading
initially to interstitial fibrosis and followed by complete
replacement of the myocardium with fibrous tissue.23 The
pathophysiologic mechanisms responsible for these alter-
ations include excessive activation of the renin-
angiotensin system,24,25 inhibition of the kallikrein-kinin
system,26 and increased expression of the tissue inhibitor
of metalloproteinase 1 and 2.23,27
Improved operative and postoperative management, to-
gether with advances in prosthetic technology, have greatly
improved the results of AVR for AS. It has been clearly
demonstrated that to optimize late patient survival, AVR
should also be considered in asymptomatic patients with
AS before severe LV hypertrophy develops. The Cleveland
Clinic group, in a retrospective observational study of more
than 3000 patients undergoing AVR for AS, found that the
presence of severe LV hypertrophy, expressed as the LV
mass index, was associated with decreased survival being
1 of the major determinants of late death.28 The importance
of LV mass regression for long-term survival has also been
stressed recently by Ali and associates.29 They demon-
strated that LV mass regression of more than 150 g
was an independent predictor of improved long-term sur-
vival on multivariate analysis after AVR at 10 years ofery c October 2012
TABLE 2. Comparative characteristics of surviving patients and
those who died of cardiac events
Characteristic
Survivors
(n ¼ 64)
Cardiac deaths
(n ¼ 20)
P
value
Mean age (y) 69  10 74  10 .040
Gender .767
Male 28 8
Female 36 12
AF 10 (16) 1 (5) .219
Diabetes 12 (19) 5 (25) .544
Arterial hypertension 26 (41) 7 (35) .653
PVD 11 (17) 4 (20) .774
Mean preoperative NYHA 2.5  0.7 2.9  0.6 .034
LVEDD (mm) 53  7 59  6 .001
LVESD (mm) 35  8 43  6 <.001
LVPWTd (mm) 12  2 11  2 .070
LVPWTs (mm) 16  3 15  3 .081
LVSWTd (mm) 14  2 13  2 .045
LVSWTs (mm) 18  3 16  3 .052
LVFS (%) 34  8 27  5 <.001
RWT 0.48  0.13 0.39  0.11 .007
LVEF (%) 55  8 46  10 <.001
LVEF<50% 12 (19) 14 (70) <.001
LVMI (g/m2) 191  31 202  38 .172
ESWS (kdyne/cm2) 105  50 165  65 <.001
Aortic PG (mm Hg) 79  18 72  19 .138
Aortic MG (mm Hg) 50  12 44  13 .063
Aortic MG<40 mm Hg 11 (17) 10 (50) .003
Aortic VAi (cm2/m2) 0.39  0.10 0.41  0.10 .375
Fibrosis grade I 22 (34) 3 (15) .098
Fibrosis grade II 31 (48) 9 (45) .788
Fibrosis grade III 11 (17) 8 (40) .033
FTMI (g/m2) 53  30 89  32 <.001
MTMI (g/m2) 77  35 85  34 .328
Data presented as mean standard deviation or numbers, with percentages in paren-
theses. MF, Myocardial fibrosis; AF, atrial fibrillation; PVD, peripheral vascular dis-
ease; NYHA, New York Heart Association functional class; LVEDD, left ventricular
end diastolic diameter; LVESD, left ventricular end-systolic diameter; LVPWTd,
left ventricular diastolic posterior wall thickness; LVPWTs, left ventricular systolic
posterior wall thickness; LVSWTd, left ventricular diastolic septal thickness; LVSWTs,
left ventricular systolic septal thickness; LVFS, left ventricular fractional shortening;
RWT, relative wall thickness; LVEF, left ventricular ejection fraction; LVMI, left ven-
tricular mass index; ESWS, end systolic wall stress; RVSP, right ventricular systolic
pressure; RVDP, right ventricular diastolic pressure; PASP, pulmonary artery systolic
pressure; PADP, pulmonary artery diastolic pressure; MWP, mean wedge pressure;
PG, peak gradient;MG,mean gradient; VAi, indexed valve area; FTMI, fibrosis tissue
mass index; MTMI, myocyte tissue mass index.
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Dfollow-up.29 The role of fibrotic changes in the hypertrophied
myocardiumof patients with severeAS in influencing the late
results of AVR has been not thoroughly investigated. We be-
lieve that information on this issue should be of great value for
the cardiac surgical community to help define better indica-
tions and timing for patients scheduled for AVR for AS.
In our study, it was possible to confirm varying degrees of
interstitial MF in all patients with AS, as demonstrated by
Hein and colleagues5; such changes were significantly
greater in the patients with severe LV dysfunction. This in-
verse relationship between MF and LV function has beenThe Journal of Thoracic and Capreviously reported.26 However, few studies have investi-
gated the relationship between the amount of MF and
LV functional recovery after AVR.5,9,19,21,30 Hein and
colleagues5 showed that a high degree of MF was the major
determinant of the persistence of severe myocardial dys-
function, even after AVR. However, according to Krayen-
buehl and associates,21 only the presence of a reduced
LVEF before AVR, but not the extent of MF, was a predictor
of persistent LV dysfunction postoperatively. However, the
LVEF is determined mainly by the radial myocardial func-
tion, which is not substantially affected by the subendocar-
dial abnormalities typical of interstitial fibrosis.31 It was
previously shown that the LVEF is reduced only in the
late stage of valvular disease when the radial and longitudi-
nal function has decreased.30 We found a strong correlation
between the degree of MF and LVEDD, LVESD, and LVFS.
To better assess the LV impairment induced by valve ste-
nosis, we evaluated the ESWS, which showed a good corre-
lation with the degree of MF. MF was increased in patients
with inadequate LV hypertrophy compared with those with
adequate hypertrophy. Moreover, in patients with adequate
hypertrophy and normalized wall stress, the increased LV
mass was related to the increment in wall thickness, rather
than to the LV diameters. In contrast, in patients with ele-
vated stress, the increment in LV mass was secondary to
a greater increase in the LV diameters, with lower LV
wall thickness.
A limitation of the present study was that it was a retro-
spective evaluation of a series of patients undergoing AVR
during a period when the modern noninvasive techniques
for MF evaluation were not yet available. We realize that
the calculation of ESWS is an obsolete technique for
the evaluation of MF; however, it has been useful in
identifying a subgroup of patients at highest risk. In recent
years, contrast-enhanced magnetic resonance imaging
has been shown to provide an accurate assessment of
myocardial necrosis and MF, not only in the setting of
myocardial infarction,32,33 but also in a variety of other
cardiomyopathies.34-36 Azevedo and colleagues10 have
shown that in patients with severe aortic valve disease, the
amount of MF, determined by either histologic examination
or contrast-enhanced magnetic resonance imaging, is asso-
ciated with the degree of LV functional improvement after
surgery. They also observed that greater degrees of MF
were associated with worse long-term survival after AVR.
Finally, the same study found patient age and the amount
of MF to be independent predictors of mortality for all
causes. Our study demonstrated that the FTMI in the sub-
group of patients who died of cardiac events was greater
than in those who were alive at late follow-up (89  32 vs
53  30, P<.001). Similarly, 10 years after AVR, patients
with a preoperatively greater amount of MF had a lower
freedom from cardiac death compared with the patients
with a lower MF grade (42%  19% vs 89%  6%,rdiovascular Surgery c Volume 144, Number 4 835
TABLE 3. Hemodynamic profile according to myocardial fibrosis grade
Variable
Fibrosis grade I Fibrosis grade II Fibrosis grade III
Preoperative
(n ¼ 28)
Postoperative
(n ¼ 28)
Preoperative
(n ¼ 52)
Postoperative
(n ¼ 50)
Preoperative
(n ¼ 19)
Postoperative
(n ¼ 18)
Mean NYHA 2.4  0.7 1.9  0.6* 2.5  0.7 2.2  0.8* 3.1  0.6 3.2  0.8
LVEDD (mm) 47  6 46  6* 54  5 53  5* 63  4 63  4
LVESD (mm) 29  6 30  5y 37  5 36  6 47  5 48  5
LVFS (%) 39  6 41  6 33  6 34  7 24  6 24  5
RWT 0.61  0.10 0.49  0.07y 0.44  0.07 0.37  0.07y 0.31  0.04 0.37  0.12*
LVEF (%) 57  7 60  10* 55  8 57  8 42  7 40  5
LVMI (g/m2) 196  33 118  30y 194  30 134  37y 190  38 173  36y
Aortic MG
(mm Hg)
50  11 13  4y 51  14 12  3y 44  12 12  3y
Aortic VAi (cm2/m2) 0.39  0.08 0.93  0.19y 0.38  0.09 0.99  0.19y 0.40  0.10 0.93  0.12y
ESWS (kdyne/cm2) 65  20 68  18 109  30 114  33 206  41 182  36y
NYHA, New York Heart Association functional class; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVFS, left ventricular frac-
tional shortening; RWT, relative wall thickness; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; MG, mean gradient; VAi, indexed valve area; ESWS,
end-systolic wall stress. *P<.05; yP<.001 (both values for within-group comparison).
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DP ¼ .002). Moreover, multivariate analysis showed that an
increased ESWS and the degree of MF were incremental
risk factors for mortality from cardiac causes.
The clinical treatment of patients with AS is determined
by the symptoms and echocardiographic parameters such as
LVEF, transvalvular gradients, and aortic valve area. How-
ever, these parameters are dependent on the stroke volume,
are not always symptom related, and do not predict the clin-
ical outcome after AVR.8 Our results have indicated that the
quantitative assessment of MF has the potential to provide
additional prognostic information in the evaluation of pa-
tients with severe AS, particularly in those with a low gra-
dient and LV dysfunction. In our study, the degree of MF
was assessed by ultrastructural evaluation of biopsy frag-
ments obtained only from the interventricular septum and
not from the entire LV wall. This, despite the relevance of
the technique, remains another potential limitation of the
study. Newer techniques especially designed for the assess-
ment of diffuse MF, such as myocardium T1-weighted
mapping and contrast-enhanced magnetic resonance imag-
ing, are now available.8,35-38 However, until these
sophisticated techniques are readily available, noninvasive
techniques such as the echocardiographic assessment of
mitral annulus displacement can be useful in identifying
patients with LV dysfunction related to MF.39 Weidemann
and colleagues,9 in evaluating patients with severe AS,
have shown that displacement of the mitral annulus greater
than 7 mm proved to be an excellent positive predictor for
LV functional improvement after AVR. More recently, the
same group, studying patients with severe AS and a low
gradient, showed a close inverse correlation between inter-
stitial fibrosis and mitral ring displacement.11 The assess-
ment of mitral ring displacement was also shown to be
useful in differentiating moderate AS with a low gradient
from severe AS with a preserved ejection fraction.11836 The Journal of Thoracic and Cardiovascular SurgIn conclusion, the results of the present study indicate
that in patients with severe AS, a reduced LV function
and increased LV diameters are strongly related to the
amount of MF, which significantly affects long-term sur-
vival after AVR. Future research should be directed to-
ward developing strategies to allow the earlier detection
of MF to improve the long-term outcomes after AVR
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